Breaking News

Financial Report: Baxter

July 17, 2014

Revenues up 16% in the quarter

Baxter
 
2Q Revenues: $4.3 billion (+16%)

2Q Earnings: $520 million (-12%)

YTD Revenues: $8.2 billion (+15%)

YTD Earnings: $1.1 billion (-6%)

Comments: BioScience revenues were up 7% to $1.8 billion in the quarter, led by double-digit growth of ADVATE and albumin, as well as increased global demand for GAMMAGARD LIQUID, biosurgery products and select vaccines. Medical Product sales were $2.5 billion, up 24%, driven primarily by strong sales of injectable drugs, anesthetics and nutritional therapies, as well as gains in peritoneal dialysis patients, particularly in the U.S. and emerging markets. Results include after-tax special items totaling $172 million, primarily for amortization and costs associated with revenue and product development milestones, remediation efforts for the in-progress SPECTRUM Infusion Pump recall, integration of Gambro AB, and Baxter’s planned separation into two independent healthcare companies.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks